{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T06:47:42Z","timestamp":1781765262829,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,25]]},"DOI":"10.7759\/cureus.26313","type":"journal-article","created":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T08:30:17Z","timestamp":1656145817000},"source":"Crossref","is-referenced-by-count":13,"title":["A Systematic Review of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Sympathetic Nervous System Inhibition: An Underrated Mechanism of Cardiorenal Protection"],"prefix":"10.7759","author":[{"given":"Shafaat","family":"Raza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Osasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudiksha","family":"Sethia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tayyaba","family":"Batool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zarna","family":"Bambhroliya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Sandrugu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwasemilore","family":"Okunlola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pousette","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.17668","article-title":"Do SGLT2 inhibitors improve cardio-renal outcomes in patients with type II diabetes mellitus: a systematic review","volume":"13","author":"Kalluri SR","year":"2021","unstructured":"Kalluri SR, Bhutta TH, Hannoodee H, et al.. Do SGLT2 inhibitors improve cardio-renal outcomes in patients with type II diabetes mellitus: a systematic review. Cureus. 2021, 13:e17668. 10.7759\/cureus.17668","journal-title":"Cureus"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13169","article-title":"Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analyses","volume":"7","author":"Butler J","year":"2020","unstructured":"Butler J, Usman MS, Khan MS, et al.. Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analyses. ESC Heart Fail. 2020, 7:3298-309. 10.1002\/ehf2.13169","journal-title":"ESC Heart Fail"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-020-01071-y","article-title":"SGLT2i: beyond the glucose-lowering effect","volume":"19","author":"Ni L","year":"2020","unstructured":"Ni L, Yuan C, Chen G, Zhang C, Wu X. SGLT2i: beyond the glucose-lowering effect. Cardiovasc Diabetol. 2020, 19:98. 10.1186\/s12933-020-01071-y","journal-title":"Cardiovasc Diabetol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01266-x","article-title":"Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients","volume":"20","author":"Xiang B","year":"2021","unstructured":"Xiang B, Zhao X, Zhou X. Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients. Cardiovasc Diabetol. 2021, 20:78. 10.1186\/s12933-021-01266-x","journal-title":"Cardiovasc Diabetol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-021-01442-z","article-title":"Renal protection with SGLT2 Inhibitors: effects in acute and chronic kidney disease","volume":"22","author":"Bailey CJ","year":"2022","unstructured":"Bailey CJ, Day C, Bellary S. Renal protection with SGLT2 Inhibitors: effects in acute and chronic kidney disease. Curr Diab Rep. 2022, 22:39-52. 10.1007\/s11892-021-01442-z","journal-title":"Curr Diab Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.119.11684","article-title":"Antihypertensive and renal mechanisms of SGLT2 (sodium-glucose linked transporter 2) inhibitors","volume":"75","author":"Wilcox CS","year":"2020","unstructured":"Wilcox CS. Antihypertensive and renal mechanisms of SGLT2 (sodium-glucose linked transporter 2) inhibitors. Hypertension. 2020, 75:894-901. 10.1161\/HYPERTENSIONAHA.119.11684","journal-title":"Hypertension"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.11.031","article-title":"Mechanisms of cardiorenal effects of sodium-glucose cotransporter\u00a02\u00a0inhibitors: JACC state-of-the-art review","volume":"75","author":"Zelniker TA","year":"2020","unstructured":"Zelniker TA, Braunwald E. Mechanisms of cardiorenal effects of sodium-glucose cotransporter\u00a02\u00a0inhibitors: JACC state-of-the-art review. J Am Coll Cardiol. 2020, 75:422-34. 10.1016\/j.jacc.2019.11.031","journal-title":"J Am Coll Cardiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/1753944720939383","article-title":"Sodium glucose cotransporter (SGLT)-2 inhibitors alleviate the renal stress responsible for sympathetic activation","volume":"14","author":"Sano M","year":"2020","unstructured":"Sano M. Sodium glucose cotransporter (SGLT)-2 inhibitors alleviate the renal stress responsible for sympathetic activation. Ther Adv Cardiovasc Dis. 2020, 14:1-6. 10.1177\/1753944720939383","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfy090","article-title":"The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study","volume":"11","author":"Herrington WG","year":"2018","unstructured":"Herrington WG, Preiss D, Haynes R, et al.. The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. Clin Kidney J. 2018, 11:749-61. 10.1093\/ckj\/sfy090","journal-title":"Clin Kidney J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review","volume":"5","author":"Lopaschuk GD","year":"2020","unstructured":"Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci. 2020, 5:632-44. 10.1016\/j.jacbts.2020.02.004","journal-title":"JACC Basic Transl Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-019-1165-1","article-title":"Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure","volume":"21","author":"Scheen AJ","year":"2019","unstructured":"Scheen AJ. Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure. Curr Cardiol Rep. 2019, 21:70. 10.1007\/s11886-019-1165-1","journal-title":"Curr Cardiol Rep"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.028268","article-title":"Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease","volume":"137","author":"Wanner C","year":"2018","unstructured":"Wanner C, Lachin JM, Inzucchi SE, et al.. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation. 2018, 137:119-29. 10.1161\/CIRCULATIONAHA.117.028268","journal-title":"Circulation"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-020-01127-z","article-title":"Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial","volume":"18","author":"Shimizu W","year":"2020","unstructured":"Shimizu W, Kubota Y, Hoshika Y, et al.. Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial. Cardiovasc Diabetol. 2020, 18:148. 10.1186\/s12933-020-01127-z","journal-title":"Cardiovasc Diabetol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic V","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al.. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019, 380:2295-306. 10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2021-002484","article-title":"Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial","volume":"9","author":"Dagogo-Jack S","year":"2021","unstructured":"Dagogo-Jack S, Pratley RE, Cherney DZ, et al.. Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial. BMJ Open Diabetes Res Care. 2021, 9:e002484. 10.1136\/bmjdrc-2021-002484","journal-title":"BMJ Open Diabetes Res Care"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.050255","article-title":"Efficacy of ertugliflozin on heart failure-related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV trial","volume":"142","author":"Cosentino F","year":"2020","unstructured":"Cosentino F, Cannon CP, Cherney DZ, et al.. Efficacy of ertugliflozin on heart failure-related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV trial. Circulation. 2020, 142:2205-15. 10.1161\/CIRCULATIONAHA.120.050255","journal-title":"Circulation"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.035901","article-title":"Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function","volume":"138","author":"Neuen BL","year":"2018","unstructured":"Neuen BL, Ohkuma T, Neal B, et al.. Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function. Circulation. 2018, 138:1537-50. 10.1161\/CIRCULATIONAHA.118.035901","journal-title":"Circulation"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott SD","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al.. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019, 380:347-57. 10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.1906","article-title":"Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes","volume":"323","author":"Petrie MC","year":"2020","unstructured":"Petrie MC, Verma S, Docherty KF, et al.. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA. 2020, 323:1353-68. 10.1001\/jama.2020.1906","journal-title":"JAMA"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13648","article-title":"Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis","volume":"21","author":"Toyama T","year":"2019","unstructured":"Toyama T, Neuen BL, Jun M, et al.. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis. Diabetes Obes Metab. 2019, 21:1237-50. 10.1111\/dom.13648","journal-title":"Diabetes Obes Metab"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire DK","year":"2021","unstructured":"McGuire DK, Shih WJ, Cosentino F, et al.. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 2021, 6:148-58. 10.1001\/jamacardio.2020.4511","journal-title":"JAMA Cardiol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-020-01048-x","article-title":"The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study","volume":"19","author":"Chen HY","year":"2020","unstructured":"Chen HY, Huang JY, Siao WZ, Jong GP. The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study. Cardiovasc Diabetol. 2020, 19:73. 10.1186\/s12933-020-01048-x","journal-title":"Cardiovasc Diabetol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-016-3956-x","article-title":"SGLT2 Inhibition and cardiovascular events: why did EMPA-REG outcomes surprise and what were the likely mechanisms?","volume":"59","author":"Sattar N","year":"2016","unstructured":"Sattar N, McLaren J, Kristensen SL, Preiss D, McMurray JJ. SGLT2 Inhibition and cardiovascular events: why did EMPA-REG outcomes surprise and what were the likely mechanisms?. Diabetologia. 2016, 59:1333-9. 10.1007\/s00125-016-3956-x","journal-title":"Diabetologia"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2017.12.004","article-title":"A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity","volume":"71","author":"Sano M","year":"2018","unstructured":"Sano M. A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity. J Cardiol. 2018, 71:471-6. 10.1016\/j.jjcc.2017.12.004","journal-title":"J Cardiol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-020-01154-w","article-title":"Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes","volume":"19","author":"Schernthaner G","year":"2020","unstructured":"Schernthaner G, Shehadeh N, Ametov AS, et al.. Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes. Cardiovasc Diabetol. 2020, 19:185. 10.1186\/s12933-020-01154-w","journal-title":"Cardiovasc Diabetol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-021-05407-5","article-title":"Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial","volume":"64","author":"Cherney DZ","year":"2021","unstructured":"Cherney DZ, Charbonnel B, Cosentino F, et al.. Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial. Diabetologia. 2021, 64:1256-67. 10.1007\/s00125-021-05407-5","journal-title":"Diabetologia"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/nep.12620","article-title":"Is it time to think about the sodium glucose co-transporter 2 sympathetically?","volume":"21","author":"Elliott RH","year":"2016","unstructured":"Elliott RH, Matthews VB, Rudnicka C, Schlaich MP. Is it time to think about the sodium glucose co-transporter 2 sympathetically?. Nephrology. 2016, 21:286-94. 10.1111\/nep.12620","journal-title":"Nephrology"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22147684","article-title":"Sympatholytic mechanisms for the beneficial cardiovascular effects of SGLT2 inhibitors: a research hypothesis for dapagliflozin's effects in the adrenal gland","volume":"22","author":"Lymperopoulos A","year":"2021","unstructured":"Lymperopoulos A, Borges JI, Cora N, Sizova A. Sympatholytic mechanisms for the beneficial cardiovascular effects of SGLT2 inhibitors: a research hypothesis for dapagliflozin's effects in the adrenal gland. Int J Mol Sci. 2021, 22:7684. 10.3390\/ijms22147684","journal-title":"Int J Mol Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/96241-a-systematic-review-of-sodium-glucose-cotransporter-2-sglt2-inhibitors-and-sympathetic-nervous-system-inhibition-an-underrated-mechanism-of-cardiorenal-protection","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:38:34Z","timestamp":1707507514000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/96241-a-systematic-review-of-sodium-glucose-cotransporter-2-sglt2-inhibitors-and-sympathetic-nervous-system-inhibition-an-underrated-mechanism-of-cardiorenal-protection"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,25]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.26313","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6,25]]}}}